Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02421367 · ClinicalTrials.gov registry record · Phase 1
Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT02421367: Completed Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
NCT02421367 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02421367, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the safety and immunogenicity and antibody persistence of the candidate dengue vaccine.
Interventions
- BIOLOGICAL TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-03 |
| Phase | Phase 1 |
What the finished NCT02421367 record still lists
NCT02421367 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 1 intervention - of which TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution. is the first listed.
NCT02421367 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02421367 about?
NCT02421367 is a clinical study titled "Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults". This study is being conducted to evaluate the safety and immunogenicity and antibody persistence of the candidate dengue vaccine.
What is the current status of trial NCT02421367?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2015-08. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02421367?
The interventions under investigation include: TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution. (BIOLOGICAL).
Who is sponsoring clinical trial NCT02421367?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02421367's enrollment target sits among peer trials
140 402nd of 2000 higher than 1,583 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia